Biopeptide

Other Names

No alternative names.

Synopsis

Biopeptides (Bioactive Peptides): A Comprehensive Reference

1. Identity: Nomenclature, Chemical Nature, and Sources

The term biopeptide — used interchangeably with bioactive peptide (BAP) or food-derived bioactive peptide — refers to a distinct class of protein-derived biomolecules that exert measurable physiological effects beyond simple nutritional provision. Bioactive peptides are specific protein-derived biomolecules that impart physiological effects and provide a positive impact on human body functions as well as health conditions. The U.S. National Institutes of Health (NIH) offers a formal definition: the NIH defines the term bioactive peptides as "compounds that are constituents in foods and dietary supplements, other than those needed to meet basic human nutritional needs, which are responsible for changes in health status."

Bioactive peptides are organic substances formed by amino acids joined by covalent bonds known as amide or peptide bonds. Their size is a defining characteristic: the short chains of amino acids with biological properties are known as bioactive peptides, and they usually contain 2–15 amino acid residues. Some authorities place the upper limit somewhat higher; bioactive peptides useful in supplemental compositions will generally be less than about 100 amino acids, less than about 50 amino acids, or less than about 20 amino acids in length.

Biopeptides carry no single botanical or chemical name because the class encompasses tens of thousands of individual sequences. Well-characterized examples include:

Isoleucine-Proline-Proline (IPP) and Valine-Proline-Proline (VPP) — milk casein-derived ACE-inhibitory tripeptides
β-Casomorphin-7 (BCM-7) — a seven-amino-acid opioid peptide (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) released from A1 β-casein
Caseinophosphopeptides (CPPs) — phosphorylated milk peptide fragments that act as mineral carriers
Lactoferricin — an antimicrobial peptide derived from lactoferrin in whey
Gly-Pro-Hyp (GPH) and related hydroxyproline-containing di- and tripeptides — characteristic collagen hydrolysate fragments

Natural Sources

There is an abundance of bioactive peptides contained in a wide range of food sources (products of plant, animal and marine origin) and generated by fermentation, enzymatic, chemical hydrolysis or gastrointestinal digestion processes from food proteins. The major source categories are:

Dairy: Dairy products such as milk and cheese are ideal options for extracting animal bioactive peptides. Most milk biopeptides are released from casein, and especially from β-casein, to which 38 bioactive peptides are attributed; these sequences can be classified mainly as angiotensin-converting enzyme (ACE) inhibitors, opioids, and antimicrobial peptides.
Collagen and gelatin: Collagen is hydrolysed enzymatically, degrading it into smaller bioactive peptides (the primary supplemental form of collagen) that are easily absorbed within the digestive tract before entering circulation. Currently, the sources of collagen peptides are bovine, porcine, marine and poultry hydrolysed collagen.
Marine organisms: Marine species represent principal natural reservoirs of bioactive peptides exhibiting antioxidant, antimicrobial, antihypertensive, and immunomodulatory properties.
Soy and legumes: Functional soybean peptides are a well-studied plant source. Immunomodulatory peptides derived from tryptic hydrolysates of rice and soybean proteins act to stimulate superoxide anions (reactive oxygen species), which triggers non-specific immune defense systems.
Eggs, meat, and fish: ACE-inhibitory peptides have also been identified from fish, eggs, soy, and grains, though the clinical evidence for these sources is less extensive than for dairy.
Wheat gluten: Peptides with opioid activities are derived from wheat gluten or casein, following digestion with pepsin.

2. Common Forms and Preparations

The bioactive peptide sequences present in food proteins are generally hidden in the inner core of the parent proteins; however, they can be released from food proteins with the help of several techniques including proteolysis, microbial fermentation, and gastrointestinal (GI) digestion.

The principal production and commercial forms are:

Enzymatic hydrolysates: Among production methods, in vitro enzymatic hydrolysis using commercial proteolytic enzymes is the widely employed method in recent times; the proteases cleave specific sites on the dietary proteins and release the short chains of bioactive peptides. Several commercial proteases, namely thermolysin, bromelain, trypsin, alcalase, papain, pepsin, neutrase, pancreatin, corolase, protamex, and pronase, have been employed to generate biologically active peptides from various dietary proteins.
Fermented food products: Cheese, yogurt, kefir, and fermented milk drinks are natural peptide-generating systems; the longer and more complex the fermentation, the more peptides are released.
Encapsulated or powdered supplements: Collagen peptide supplements are provided in either a capsule or powdered form, consumed with water. Milk-derived peptide concentrates such as IPP-rich milk protein hydrolysates are similarly available in capsule form.
Functional foods and beverages: Some peptides, like the blood-pressure-lowering tripeptides VPP and IPP from fermented milk, have been commercialized as functional foods.
Chemically synthesized peptides: Some bioactive peptides have been prepared by chemical synthesis.

3. Traditional and Historical Use

Biopeptides, as a discrete pharmacological concept, are a product of late-20th-century food science. However, the foods richest in bioactive peptides have very long histories of use across multiple cultures, where empirical observation of health benefits — particularly digestive comfort, vitality, and longevity — preceded any mechanistic understanding.

Fermented dairy products have been prepared and consumed for millennia. Kefir is a fermented dairy beverage which is traditional in Eastern Europe. It is considered to originate from the Caucasus region and the Balkans in Eastern Europe. In those traditions, kefir was historically regarded as a restorative drink associated with longevity and gastric health, attributes now partially attributable to the peptides released during fermentation. Similarly, aged cheeses such as Parmesan and Gouda have been produced in Europe since the medieval period, and aged cheeses like Parmesan and Gouda contain particularly high concentrations of bioactive peptides because months or years of bacterial proteolysis break casein into thousands of fragments.

Dairy goods such as yogurt, cheese, and kefir; soy-based items like miso, tempeh, kinema, and soy sauce; and fish products like fermented fish sauce are all sources of bioactive peptides with traditional use across multiple cultures. Miso and tempeh have been central to Japanese and Southeast Asian diets, respectively, for centuries. Fish sauce fermentation has been practiced in East and Southeast Asia for over two thousand years, and all of these processes inherently generate biopeptides through microbial and enzymatic breakdown of source proteins.

The scientific study of biopeptides began in earnest in the late 1970s, when opioid activity was first identified in milk. Milk was indicated to have opioid activity in 1979, and morphine was isolated from milk as a drug at concentrations of 200 to 500 ng/L. Research on biopeptides derived from fermented foods gained broader prominence later: research on these peptides from fermented foods gained prominence in the late 20th century, with early findings by Yamamoto et al. (1994) linking peptides in yogurt-like products to antihypertensive effects.

Gelatine and bone broths, prepared from collagen-rich connective tissue and bones of animals, have been used in traditional cooking from Chinese, European, and Middle Eastern traditions to promote joint comfort and recovery from illness. While these preparations were not analyzed chemically until modern times, they represent an early empirical form of collagen peptide consumption, the bioactive significance of which is now supported by contemporary research.

4. Key Constituents and Active Compounds

The functional character of a biopeptide resides in its specific amino acid sequence. The activity of a peptide depends on its structure, i.e., the amino acid composition, the type of N- and C-terminal amino acid, the length of the peptide chain, charge character of the amino acids forming the peptide, and the hydrophobic/hydrophilic characteristics of the amino acid chain.

The most important constituent classes are:

ACE-Inhibitory Peptides

Hydrolysis of the milk protein casein yields at least 2 bioactive peptides with ACE inhibitor actions, namely IPP (Ile-Pro-Pro) and VPP (Val-Pro-Pro). Peptides with higher ACE inhibitory activity usually have aromatic or basic N-terminal amino acids, and higher quantities of hydrophobic and positively charged amino acids at the C-terminal.

Opioid Peptides (Casomorphins and Exorphins)

β-Casomorphin-7 (BCM-7) is a bioactive peptide with a seven-amino-acid chain (Tyr60-Pro61-Phe62-Pro63-Gly64-Pro65-Ile66) with opioid characteristics. Exorphins, or opioid peptides derived from food proteins such as wheat and milk (exogenous sources), have a similar structure to endogenous opioid peptides, with a tyrosine residue located at the amino terminal or bioactive site.

Caseinophosphopeptides (CPPs)

Caseinophosphopeptides can form soluble organophosphate salts and may function as carriers for different minerals, especially calcium.

Collagen-Derived Peptides

Collagen is characterised by a high concentration of three amino acids — glycine, proline, and hydroxyproline — which create its characteristic triple-helix structure. Upon hydrolysis, characteristic fragments such as Pro-Hyp, Hyp-Gly, Gly-Pro-Hyp, and Pro-Gly are generated and are detectable in human blood after ingestion. Gly-Pro-type peptides consisting of 4–9 amino acids are the most potent DPP-IV inhibitory peptides in collagen.

Antimicrobial Peptides (AMPs)

Antimicrobial peptides are chains of amino acids mostly with molecular weight below 10 kDa and containing fewer than 50 amino acids.

5. Mechanisms of Action

Dietary biopeptides have been shown to positively affect the various systems of the human body including the immune, cardiovascular, gastrointestinal, and nervous systems. The mechanisms through which they act are diverse and sequence-dependent.

ACE Inhibition and Blood Pressure Regulation

ACE, as part of the renin-angiotensin system (RAS), has an important role in the regulation of blood pressure by converting angiotensin I to a potent vasoconstrictor, angiotensin II, which induces the release of aldosterone and therefore increases sodium concentration and blood pressure further. IPP and VPP competitively inhibit this enzyme. Additionally, a number of bioactive peptides from eggs, milk, and seafood sources have been validated for their anti-hypertensive actions, involving multiple functional modalities including inhibition of ACE, amelioration of inflammation, generation of vasodilators like nitric oxide, and the reduction in vascular oxidative stress.

Antioxidant Activity

Many food-derived peptides scavenge free radicals, chelate pro-oxidant metal ions, or inhibit lipid peroxidation in laboratory assays. Peptides from different sources, such as milk, sunflower, garlic, and meat, have been shown to be able to activate the Keap1/Nrf2 axis, showing antioxidant properties and at the same time anti-inflammatory abilities due to the consequent inhibition of the pro-inflammatory pathway mediated by NF-κB, with a consequent decrease in cytokine release.

Anti-Inflammatory and Immunomodulatory Action

Bioactive peptides treat inflammation by regulating the release of inflammatory mediators, modulating mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB) signaling pathways, and reducing oxidative stress response for immunomodulation. Immunomodulating casein peptides stimulate proliferation of human lymphocytes and phagocytic activities of macrophages.

Antimicrobial Action

AMPs can bind to and penetrate the bacterial membrane and then interact with the phospholipid components of the cytoplasmic membrane, leading to pore formation, which disrupts membrane integrity, causing leakage of cellular contents and leading to cell lysis and death. In addition to disrupting membranes, AMPs can also target essential cellular mechanisms within pathogens through binding to DNA, RNA, and protein and inhibiting their functions, further contributing to microbial destruction.

DPP-IV Inhibition (Antidiabetic Action)

Dipeptidyl peptidase (DPP-IV), a glycoprotein with serine exopeptidase activity, may cleave incretins including glucagon-like peptide-1 (GLP-1) and glucose inhibitory polypeptide (GIP), which has been proven to increase blood sugar levels. Certain food-derived peptides, particularly those from collagen, casein, and fish gelatin, inhibit DPP-IV, thereby prolonging GLP-1 activity. Certain peptides not only inhibit DPP-IV but also stimulate GLP-1 secretion, enhancing their therapeutic potential.

Opioid Receptor Interaction

β-casomorphins bind to a µ-opioid receptor mainly in the gastrointestinal tract and central nervous system. Opioid peptides are opioid receptor ligands with agonistic or antagonistic activities. The physiological consequences of this interaction in humans who consume dairy foods at ordinary dietary levels remain an active area of investigation.

Antithrombotic Action

Antithrombotic peptides inhibit fibrinogen binding to a specific receptor region on the platelet surface and also inhibit aggregation of platelets.

Mineral Transport

Antioxidant properties that prevent peroxidation of essential fatty acids have also been shown for peptides derived from milk proteins. Caseinophosphopeptides enhance the solubility and intestinal absorption of calcium, iron, and zinc by forming stable, soluble complexes with these minerals in the intestinal lumen.

Neuroprotective Action

Specific peptides exhibit neuroprotective effects by crossing the blood–brain barrier and exerting antioxidant and anti-inflammatory actions within the nervous system; derived from milk proteins, fish, and select plant sources, these neuroprotective peptides show promise in reducing the risk of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. This evidence is currently preliminary and largely preclinical.

6. Scientific Evidence by Area of Use

6.1 Cardiovascular Health: Blood Pressure Reduction

This is the most extensively studied area for biopeptides in human clinical research. The best-characterized peptides found in fermented or enzymatically treated milk are IPP and VPP; over twenty-five human studies have been performed linking the consumption of products containing both IPP and VPP with significant reductions in blood pressure. Fifteen of these blood pressure studies have been done in Japanese subjects, while ten studies have been performed in Caucasian subjects, that is, in Finnish, Dutch, Scottish, and American subjects.

A key randomized, double-blind, placebo-controlled crossover trial enrolled 70 Caucasian subjects with prehypertension or stage 1 hypertension. Study treatments consisted of daily consumption of two capsules MPH1 (each containing 7.5 mg IPP), MPH2 (each containing 6.6 mg MAP, 2.3 mg LPP, 1.8 mg IPP), or placebo (containing cellulose) for 4 weeks.

Despite this body of positive evidence, the results are not uniform. A randomized, double-blind, placebo-controlled trial published in Hypertension by the American Heart Association enrolled 135 Dutch subjects with elevated systolic blood pressure who were otherwise healthy and who received no current antihypertensive treatment. After a 2-week run-in period, subjects randomly received a daily dose of 200 mL dairy drink with 14 mg lactotripeptides obtained by concentrating fermented milk, enzymatic hydrolysis, or chemical synthesis, or placebo for 8 weeks. This randomized double-blind controlled trial provided no evidence for a blood pressure lowering effect of the lactotripeptides IPP and VPP in human subjects with untreated elevated blood pressure.

Meta-analytic evaluation of the literature has been similarly inconclusive: three recent meta-analyses have resulted in non-conclusive results about the efficacy of milk-derived biopeptides in the reduction of hypertension. Bioactive peptides derived from fish, milk, meat, and plants have demonstrated significant antihypertensive and lipid-lowering activity in clinical trials, but effect sizes are modest and context-dependent. Overall, the evidence for IPP/VPP antihypertensive activity in humans is mixed, with positive effects more consistently observed in Japanese populations and in hypertensive rather than normotensive subjects.

6.2 Skin Health: Hydration, Elasticity, and Aging

Bioactive collagen peptides are the principal biopeptides studied for dermal outcomes. Clinical doses for skin-health benefits range from 2.5 g to 5 g per day, whereas doses of 10–20 g/day have been used to improve muscle function. A randomized, double-blind, placebo-controlled clinical study administered 5,000 mg of bioactive collagen peptides (BCP) derived from bovine type I collagen daily. The intervention continued for 12 weeks, followed by a 4-week washout period to evaluate the durability of any observed skin effects. Several other controlled trials have similarly examined oral collagen peptide supplementation for 4 to 12 weeks for effects on skin elasticity and wrinkling. Other clinical studies showed that collagen hydrolysate intake for 4 to 12 weeks affects skin elasticity.

The evidence for skin outcomes from collagen peptides is relatively consistent across small-to-medium randomized controlled trials, though effect sizes are modest. Evidence is rated preliminary to moderate strength.

6.3 Bone Health

Supplementation with bioactive collagen peptides led to a clinically relevant increase in bone mineral density (BMD) in the spine; these findings were consistent with the results for the femoral neck, and long-term supplementation with specific bioactive collagen peptides appears to be effective in counteracting losses in BMD. The peptides used in this study derived from specific hydrolysis of type I collagen with a mean molecular weight of about 5 kDa; the test product was packed in single sachets containing a daily dose of 5 g, dissolved in 250 mL of water.

Evidence here is promising but limited in scope; larger confirmatory trials are needed.

6.4 Joint and Musculoskeletal Health

Fifteen studies were included in a systematic review examining collagen peptides; of these, 8 used collagen peptides or collagen hydrolysate in doses of 5–15 g/day. Outcomes included markers of joint comfort and collagen synthesis biomarkers. Only Shaw et al. (2017) found that bone collagen synthesis marker PINP increased significantly with collagen (15 g dose only), whereas Clifford et al. (2019) and Lis and Baar (2019) did not observe any changes in PINP following 20 g/day collagen and varied doses (15 g gelatine enriched with vitamin C, 15 g hydrolysed collagen, and a 15 g gummy containing 7.5 g gelatine and 7.5 g hydrolysed collagen), respectively. The overall evidence for joint outcomes is mixed to moderate, with some benefits observed particularly for pain reduction in activity-related joint discomfort.

6.5 Diabetes: DPP-IV Inhibition and Glycemic Control

Many in vitro and some in vivo studies have highlighted the potential of food-derived peptides functioning as effective DPP-IV inhibitors. In animal models, a porcine skin gelatin hydrolysate (PGH) demonstrated meaningful antidiabetic effects: the DPP-IV activities of the diabetic rats administered PGH and sitagliptin after 42 days were 50.0% and 31.0% lesser than the diabetic control rats, respectively; PGH had a superior antidiabetic effect in STZ-induced diabetic rats, including improvement of glucose tolerance, elevation of plasma insulin and GLP-1 levels, inhibition of DPP-IV activity, and reduction of glucagon levels.

However, although there have been many in vitro DPP-IV inhibitory peptides or protein hydrolysates reported, their in vivo effects on diabetic animals or patients have rarely been studied; more detailed in vivo studies to evaluate the efficacy, safety, bioavailability, and potency of inhibitory peptides and/or protein hydrolysates are needed. Evidence for this indication is currently preliminary and primarily preclinical; robust human clinical trials are lacking.

6.6 Antioxidant and Anti-Inflammatory Effects

Dietary biopeptides have been shown to positively affect various systems of the human body including the immune, cardiovascular, gastrointestinal, and nervous systems. BAPs exhibit a wide array of functions including antimicrobial, antioxidative, anti-inflammatory, memory-enhancing, antithrombotic, and antihypertensive activities, as well as regulation of gastrointestinal absorption, appetite suppression, opioid modulation, immune modulation, and cell regulation. The great majority of antioxidant and anti-inflammatory evidence for biopeptides is derived from in vitro and animal studies; direct human clinical evidence in this area is limited and evidence strength is weak to preliminary.

6.7 Antimicrobial Applications

Another important class of bioactive peptides demonstrates antimicrobial properties, inhibiting the growth of pathogenic bacteria and fungi; found in dairy, egg, and legume proteins, these antimicrobial peptides disrupt bacterial membranes and serve as potential alternatives to traditional antibiotics, offering solutions to the growing challenge of antibiotic resistance. Most antimicrobial peptides from seafood have antibacterial activities against both Gram-negative and Gram-positive strains. Current evidence for clinical antimicrobial use of dietary biopeptides in humans is very preliminary; most data are from laboratory studies.

6.8 Immunomodulation

Although it has been established that marine-derived peptides support the immune system by promoting lymphocyte proliferation, enhancing natural killer (NK) cell activity, and regulating cytokines, the precise mechanisms of their action remain unclear. AMPs have immunomodulatory properties, activating interleukins, chemokines, and cytokines to enhance the immune response and aid in clearing pathogens from the body. Human clinical immunomodulatory evidence for dietary biopeptides as supplements is preliminary.

7. Body Systems and Health Areas

Bioactive peptides play a significant role in human health by affecting the digestive, endocrine, cardiovascular, immune, and nervous systems. Specific associations by system are:

Cardiovascular system: Blood pressure regulation via ACE inhibition; antithrombotic effects via platelet aggregation inhibition
Musculoskeletal system: Collagen peptides associated with bone mineral density maintenance and joint comfort
Integumentary system: Collagen peptides associated with skin hydration, elasticity, and wrinkle reduction
Endocrine/metabolic system: DPP-IV inhibition with effects on GLP-1 and glycemic control
Immune system: Lymphocyte proliferation, NK cell activation, cytokine regulation
Gastrointestinal system: Modulation of intestinal motility via opioid receptors; gut barrier support; microbiota modulation
Nervous system: Opioid receptor binding (central nervous system); potential neuroprotection
Mineral absorption: CPPs as calcium, zinc, and iron carriers in the intestine

8. Dosage Forms and Reported Dosages

Biopeptides are commercially available in a variety of forms. Supplements are provided in either a capsule or powdered form, consumed with water. The following dosages have been reported in peer-reviewed clinical studies:

Milk-derived IPP/VPP peptides (antihypertensive): Effective dosages range from 3.07 mg/d (1.60 mg IPP and 1.47 mg VPP) to 52.5 mg/d (30 mg IPP and 22.5 mg VPP). In the crossover RCT described above, a daily dose of 200 mL dairy drink with 14 mg lactotripeptides was administered for 8 weeks.
Collagen hydrolysate (skin health): Clinical doses for skin-health benefits range from 2.5 g to 5 g per day, whereas doses of 10–20 g/day have been used to improve muscle function; in one trial, participants received either 5,000 mg of BCP or a matching placebo once daily.
Collagen hydrolysate (bone health): The test product was packed in single sachets containing a daily dose of 5 g, dissolved in 250 mL of water at room temperature and ingested once daily.
Collagen hydrolysate (musculoskeletal/joint): Studies used collagen peptides or collagen hydrolysate in doses of 5–15 g/day.

A randomized crossover bioavailability study investigated single-dose intake of skin- and hide-derived collagen hydrolysate from fish, porcine, and bovine origin with different molecular weights (bovine 2,000 and 5,000 Da). Independently of source and molecular weight, all collagen hydrolysates yielded relevant plasma concentrations of the investigated metabolites.

9. Bioavailability

The biopeptides must cross the GI barrier and reach the target tissue or organ in order to exhibit health benefits. The feasibility of pharmacological application of these peptides depends on absorption and bioavailability in intact forms in target tissues, which in turn depends on the structure of the peptides. A significant challenge specific to biopeptides is their susceptibility to further digestion in the gut: the oral bioavailability of these peptides remains a significant challenge due to enzymatic degradation and poor absorption, which limits their clinical translation; systemic circulation is required for peptides to exert in vivo bioactivity.

For collagen-derived peptides, the picture is somewhat more favorable: a higher amount of total compared to free hydroxyproline indicated the uptake of substantial amounts of Hyp-containing di- or tripeptides; independently of source and molecular weight, all collagen hydrolysates yielded relevant plasma concentrations of the investigated metabolites. Pharmacokinetic analysis with casein-derived peptides demonstrated oral bioavailability of 11.28% and 19.12% for specific peptides in rats, surpassing typical expectations for peptide-based agents, with these results providing evidence that the peptides exert glucose-lowering effects through the dual mechanisms of DPP-IV inhibition and GLP-1 stimulation, combined with favorable oral absorption profiles.

10. Safety Considerations and Interactions

Bioactive peptides derived from food proteins are continuing to gain momentum as important constituents of functional food ingredients and nutraceuticals; although there is a burgeoning body of literature about preparation, characterization, and activity study of food-derived bioactive peptides, and several bioactive peptides have been commercialized, there is a lack of systematic review on the safety of food protein-derived bioactive peptides.

Allergenicity

Some protein breakdown products, i.e. peptide fragments, may conserve part of the allergenicity of the native protein and thus can also be considered as allergens. The data presented on the relationship between the structure of food proteins and peptides and their allergenicity shows the difficulty in trying to assess the "non-allergenicity" of products derived from an allergenic source, even if the process used involved extensive hydrolysis of the native protein(s). People with milk allergies should avoid dairy-derived peptide products, and those with celiac disease should avoid wheat-derived peptides.

Dose, Frequency, and Duration

Administration dose, frequency, and length of use all contribute to peptide safety. At dietary doses from food, no significant adverse effects have been reported; the concentrations of bioactive peptides in food are far below the levels that would be needed to produce drug-like side effects.

Possible Toxicity from Impurities

Some toxic and allergenic peptides also show bioactivities; racemization and modification/derivation of amino acids during processing can contribute to peptide safety concerns. The formation of allergenic and toxic peptides from their parent proteins, as well as hazardous compounds during protein extraction, protein pretreatment, and bioactive peptide preparation, represents a genuine safety consideration.

β-Casomorphin-7: Specific Considerations

The possible effects of BCM-7 on health are a theme rising in popularity due to evidence found in several studies on the modulation of gastrointestinal pro-inflammatory responses that can trigger digestive symptoms, such as abdominal discomfort. Associations between BCM-7 and conditions such as autism and schizophrenia have been proposed in some studies, but these associations remain highly contested and have not been established by controlled clinical evidence.

Interactions with Antihypertensive Medications

Because ACE-inhibitory biopeptides (IPP, VPP) share a mechanistic pathway with pharmaceutical ACE inhibitor drugs (e.g., lisinopril, enalapril), concurrent use could theoretically potentiate antihypertensive effects. No formal pharmacokinetic drug interaction trials have been published in the primary peer-reviewed literature at the time of this writing.

Interactions with Antidiabetic Medications

The inhibitory efficacy of food-derived DPP-IV inhibitory peptides is analogous to that of synthetic drugs like sitagliptin; by inhibiting DPP-4-mediated breakdown of GLP-1, these peptides extend the hormone's bioavailability. Co-administration with pharmaceutical DPP-IV inhibitors (gliptins) could therefore theoretically produce additive effects on GLP-1 levels. No clinical interaction data are available.

Regulatory Status

The term 'bioactive compound' is not defined in European regulations; however, since they can be part of food supplements, fortified foods, or novel food, they are included within the legal requirements of those corresponding types of foods or supplements. Although the responsibility for the safety of these compounds lies with the food business operator placing the product on the market, the European Food Safety Authority (EFSA) carries out scientific evaluations to assess the risks for human health. In the United States, food-derived biopeptides used in supplements are regulated under the Dietary Supplement Health and Education Act (DSHEA) framework and do not require pre-market approval, though safety claims remain the manufacturer's responsibility.

Evidence Limitations and Research Gaps

The commercial application of these bioactive peptides has been delayed because of the absence of appropriate and scalable production methods, proper exploration of the mechanisms of action, high gastrointestinal digestibility, variable absorption rate, and the lack of well-designed clinical trials to provide the substantial evidence for potential health claims. Future research efforts on bioactive peptides should be directed toward elucidation of their in vivo molecular mechanisms of action, safety at various doses, and pharmacological activity in maintaining homeostasis during aberrant health conditions in human subjects.

References

Health Conditions

Health conditions that Biopeptide may help support.

No conditions available.

Body Systems

Body systems that Biopeptide may help support.

No body systems available.